The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders

Human Mutation

Volumn 29, Issue 8, 2008, Pages 992-1006

  Aoki, Yoko ^a   Niihori, Tetsuya ^a   Narumi, Yoko ^a   Kure, Shigeo ^a   Matsubara, Yoichi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; CFC syndrome; Costello syndrome; HRAS; KRAS; MAP2K1; MAP2K2; MAPK; Noonan syndrome; Oncogene; PTPN11; RAS

Indexed keywords

RAS PROTEIN;

B RAF KINASE GENE; CARDIO FACIO CUTANEOUS SYNDROME; COSTELLO SYNDROME; DISEASE MODEL; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN GENOME; KRAS GENE; LEOPARD SYNDROME; MITOGEN ACTIVATED PROTEIN KINASE 1 GENE; NEUROFIBROMATOSIS; NONHUMAN; NOONAN SYNDROME; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR TYPE 11 GENE; REVIEW;

ANIMALS; GENETIC DISEASES, INBORN; HUMANS; MAP KINASE SIGNALING SYSTEM; RAS PROTEINS; SYNDROME;

ANIMALIA;

EID: 49149115868     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20748     Document Type: Review

References (128)

1. Al-Rahawan MM, Chute DJ, Sol-Church K, Gripp KW, Stabley DL, McDaniel NL, Wilson WG, Waldron PE. 2007. Hepatoblastoma and heart transplantation in a patient with cardio-facio-cutaneous syndrome. Am J Med Genet A 143:1481-1488.
2. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. 2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040.
3. Araki T, Mohi MG, Ismat FA, Branson RT, Williams IR, Kutok JL, Yang W, Pao Ll, Gilliland DG, Epstein JA, Neel BG. 2004. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpnll mutation. Nat Med 10:849-857.
4. Arrandale JM, Gore-Willse A, Rocks S, Ren JM, Zhu J, Davis A, Livingston JN, Rabin DU. 1996. Insulin signaling in mice expressing reduced levels of Syp. J Biol Chem 271:21353-21358.
5. Bailleul B, Surani MA, White S, Barton SC, Brown K, Blessing M, Jorcano J, Balmain A. 1990. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. Cell 62:697-708.
6. Barbacid M. 1987. ras genes. Annu Rev Biochem 56:779-827.
7. Belanger LF, Roy S, Tremblay M, Brott B, Steff AM, Mourad W, Hugo P, Erikson R, Charron J. 2003. Mek2 is dispensable for mouse growth and development. Mol Cell Biol 23:4778-4787.
8. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyetson M, Sellers WR, Neel BG. 2004. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64:8816-8820.
9. Bertola DR, Pereira AC, Albano LM, De Oliveira PS, Kim CA, Krieger JE. 2006. PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. Genet Test 10:186-191.
10. Binder G, Neuer K, Ranke MB, Wittekindt NE. 2005. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 90:5377-5381.
11. Borrello MG, Pierotti MA, Bongarzone I, Donghi R, Mondellini P, Della Porta G. 1987. DNA methylation affecting the transforming activity of the human Ha-ras oncogene. Cancer Res 47:75-79.
12. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R, Somers R, Messiaen L, De Schepper S, Fryns JP, Cools J, Marynen P, Thomas G, Yoshimura A, Legius E. 2007. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 39:1120-1126.
13. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341-6350.
14. Capon DJ, Chen EY, Levinson AD, Seeburg PH, Goeddel DV. 1983. Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302:33-37.
15. Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M. 2006. Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome Phenotype. Am J Hum Genet 79:129-135.
16. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113:528-538.
17. Cohen JB, Broz SD, Levinson AD. 1989. Expression of the H-ras protooncogene is controlled by alternative splicing. Cell 58:461-472.
18. Costello J. 1971. A new syndrome. NZ Med J 74:397.
19. Costello JM. 1977. A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J 13:114-118.
20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
21. Der CJ, Krontiris TG, Cooper GM. 1982. Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79:3637-3640.
22. Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, Pizzuti A, Dallapiccola B. 2002. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet 71:389-394.
23. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
24. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, Lopez E, Malumbres M, McKay R, Ward JM, Pellicer A, Santos E. 2001. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 21:1444-1452.
25. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. 2006. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140:8-16.
26. Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M. 1984. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci USA 81:4008-4012.
27. Feng GS. 1999. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 253:47-54.
28. Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA. 2005. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 90:5156-5160.
29. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. 2001. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249-3262.
30. Fragale A, Tartaglia M, Wu J, Gelb BD. 2004. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23:267-277.
31. Garnett MJ, Marais R. 2004. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319.
32. Giehl K. 2005. Oncogenic Ras in tumour progression and metastasis. Biol Chem 386:193-205.
33. Giovannini L, Cave H, Ferrero-Vacher C, Boutte P, Sirvent N. 2005. A new PTPN11 mutation in juvenile myelomonocytic leukaemia associated with Noonan syndrome. Acta Paediatr 94:636-637.
34. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, Larouche L, Rousseau S, Huot J, Landry J, Jeannotte L, Charron J. 1999. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 9:369-372.
35. Gripp KW, Scott CI, Jr, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, Lin AE, Zackai EH. 2002. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 108:80-87.
36. Gripp KW. 2005. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137:72-77.
37. Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI, Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. 2006a. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140:1-7.
38. Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. 2006b. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A 140:2163-2169.
39. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. 2003. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:111-120.
40. Guil S, de La Iglesia N, Fernandez-Larrea J, Cifuentes D, Ferrer JC, Guinovart JJ, Bach-Elias M. 2003. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Res 63:5178-5187.
41. Hanna N, Montagner A, Lee WH, Miteva M, Vidal M, Vidaud M, Parfait B, Raynal P. 2006. Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3 K binding on Gab1. FEBS Lett 580:2477-2482.
42. Hennekam RC. 2003. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117:42-48.
43. Heumann R, Goemans C, Bartsch D, Lingenhohl K, Waldmeier PC, Hengerer B, Allegrini PR, Schellander K, Wagner EF, Arendt T, Kamdem RH, Obst-Pernberg K, Narz F, Wahle P, Berns H. 2000. Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration. J Cell Biol 151:1537-1548.
44. Hobbs RM, Silva-Vargas V, Groves R, Watt FM. 2004. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 123:503-515.
45. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. 1998. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441-450.
46. Huang MY, Cohen JB. 1997. The alternative H-ras protein p19 displays properties of a negative regulator of p21Ras. Oncol Res 9:611-621.
47. Hunter JJ, Tanaka N, Rockman HA, Ross J, Jr, Chien KR. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 270:23173-23178.
48. Ion A, Tartaglia M, Song X, Kalidas K, van der Burgt I, Shaw AC, Ming JE, Zampino G, Zackai EH, Dean JC, Somer M, Parenti G, Crosby AH, Patton MA, Gelb BD, Jeffery S. 2002. Absence of PTPN11 mutations in 28 cases of cardiofaciocutaneous (CFC) syndrome. Hum Genet 111:421-427.
49. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243-3248.
50. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T. 1997. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 11:2468-2481.
51. Johnson JP, Golabi M, Norton ME, Rosenblatt RM, Feldman GM, Yang SP, Hall BD, Fries MH, Carey JC. 1998. Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr 133:441-448.
52. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-1116.
53. Katsuki M, Kimura M, Hata J, Takahashi R, Nozawa S, Yokoyama M, Izawa M, Sekiya T, Nishimura S, Nomura T. 1989. Embryonal tumors from transgenic mouse zygotes carrying human activated c-Ha-ras genes. Mol Biol Med 6:567-572.
54. Kavamura MI, Pomponi MG, Zollino M, Lecce R, Murdolo M, Brunoni D, Alchome MM, Opitz JM, Neri G. 2003. PTPN11 mutations are not responsible for the Cardiofaciocutaneous (CFC) syndrome. Eur J Hum Genet 11:64-68.
55. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. 2005. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem 280:30984-30993.
56. Keren B, Hadchouel A, Saba S, Sznajer Y, Bonneau D, Leheup B, Boute O, Gaillard D, Lacombe D, Layet V, Marlin S, Mortier G, Toutain A, Beylot C, Baumann C, Verloes A, Cave H. 2004. PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. J Med Genet 41:e117.
57. Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cavé H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G. 2006. Genotype-phenotype correlation in Costello syndrome; HRAS mutation analysis in 43 cases. J Med Genet 43:401-405.
58. Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T, Otani H, Aiba A, Katsuki M. 1997. K-ras is essential for the development of the mouse embryo. Oncogene 15:1151-1159.
59. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 281:6785-6792.
60. Kosaki K, Suzuki T, Muroya K, Hasegawa T, Sato S, Matsuo N, Kosaki R, Nagai T, Hasegawa Y, Ogata T. 2002. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab 87:3529-3533.
61. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstrasser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML. 2005. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 106:2183-2185.
62. Kushner SA, Elgersma Y, Murphy GG, Jaarsma D, van Woerden GM, Hojjati MR, Cui Y, LeBoutillier JC, Marrone DF, Choi ES, De Zeeuw CI, Petit TL, Pozzo-Miller L, Silva AJ. 2005. Modulation of presynaptic plasticity and learning by the H-ras/extracellular signal-regulated kinase/synapsin I signaling pathway. J Neurosci 25:9721-9734.
63. Land H, Parada LF, Weinberg RA. 1983. Cellular oncogenes and multistep carcinogenesis. Science 222:771-778.
64. Legius E, Schrander-Stumpel C, Schollen E, Pulles-Heintzberger C, Gewillig M, Fryns JP. 2002. PTPN11 mutations in LEOPARD syndrome. J Med Genet 39:571-574.
65. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y. 2006. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 91:300-306.
66. Loh ML, Reynolds MG, Vattikuti S, Gerbing RB, Alonzo TA, Carlson E, Cheng JW, Lee CM, Lange BJ, Meshinchi S. 2004a. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia 18:1831-1834.
67. Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM. 2004b. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103:2325-2331.
68. Loh ML, Martinelli S, Cordeddu V, Reynolds MG, Vattikuti S, Lee CM, Wulfert M, Germing U, Haas P, Niemeyer C, Beran ME, Strom S, Lubbert M, Sorcini M, Estey EH, Gattermann N, Tartaglia M. 2005. Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res 29:459-462.
69. Lu W, Gong D, Bar-Sagi D, Cole PA. 2001. Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. Mol Cell 8:759-769.
70. Lurie IW. 1994. Genetics of the Costello syndrome. Am J Med Genet 52:358-359.
71. Maheshwari M, Belmont J, Fernbach S, Ho T, Molinari L, Yakub I, Yu F, Combes A, Towbin J, Craigen WJ, Gibbs R. 2002. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum Mutat 20:298-304.
72. Malumbres M, Barbacid M. 2003. RAS oncogenes: the first 30 years. Nat Rev Cancer 3:459-465.
73. Manabe T, Aiba A, Yamada A, Ichise T, Sakagami H, Kondo H, Katsuki M. 2000. Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. J Neurosci 20:2504-2511.
74. Mercer KE, Pritchard CA. 2003. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40.
75. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, Marais R, Pritchard C. 2005. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65:11493-11500.
76. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. 2001. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20:6551-6558.
77. Mohi MG, Neel BG. 2007. The role of Shp2 (PTPN11) in cancer. Curr Opin Genet Dev 17:23-30.
78. Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, Wieczorek D, Hinkel GK, Tinschert S, Hoeltzenbein M, Ropers HH, Kaischeuer VM. 2003. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan Syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11:201-206.
79. Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y. 2007. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome. Am J Med Genet A 143:799-807.
80. Neel BG, Gu H, Pao L. 2003. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28:284-293.
81. Neri G, Zollino M, Reynolds JF. 1991. The Noonan-CFC controversy. Am J Med Genet 39:367-370.
82. Niihori T, Aoki Y, Ohashi H, Kurosawa K, Kondoh T, Ishikiriyama S, Kawame H, Kamasaki H, Yamanaka T, Takada F, Nishio K, Sakurai M, Tamai H, Nagashima T, Suzuki Y, Kure S, Fujii K, Imaizumi M, Matsubara Y. 2005. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. J Hum Genet 50:192-202.
83. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. 2006. Germline KRAS and BRAF mutations in cardiofacio-cutaneous syndrome. Nat Genet 38:294-296.
84. Noonan JA. 1968. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373-380.
85. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. 2004. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192-1197.
86. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007-1012.
87. Plowman SJ, Hancock JF. 2005. Ras signaling from plasma membrane and endomembrane microdomains. Biochim Biophys Acta 1746:274-283.
88. Rauen KA. 2006. Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet A 140:1681-1683.
89. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Arno R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R. 2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013-1017.
90. Reddy EP, Reynolds RK, Santos E, Barbacid M. 1982. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300:149-152.
91. Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV, Opitz JM. 1986. New multiple congenital anomalies/mental retardation syndrome with cardio-facio-cutaneous involvement - the CFC syndrome. Am J Med Genet 25:413-427.
92. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. 2007. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 39:70-74.
93. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. 2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287-1290.
94. Sarkozy A, Conti E, Seripa D, Digilio MC, Grifone N, Tandoi C, Fazio VM, Di Ciommo V, Marino B, Pizzuti A, Dallapiccola B. 2003. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J Med Genet 40:704-708.
95. Sarkozy A, Conti E, Digilio MC, Marino B, Morini E, Pacileo G, Wilson M, Calabro R, Pizzuti A, Dallapiccola B. 2004. Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. J Med Genet 41:e68.
96. Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS, Pawson T. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J 16:2352-2364.
97. Schollen E, Matthijs G, Gewillig M, Fryns JR. Legius E. 2003. PTPN11 mutation in a large family with Noonan syndrome and dizygous twinning. Eur J Hum Genet 11:85-88.
98. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kaischeuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. 2006. Germline KRAS mutations cause Noonan syndrome. Nat Genet 38:331-336.
99. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. 1984. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:71-75.
100. Servidei T, Aoki Y, Lewis SE, Symes A, Fink JS, Reeves SA. 1998. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2. J Biol Chem 273:6233-6241.
101. Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, Kamata T, Feramisco J, Stavnezer E, Fogh J, Wigler MH. 1983. Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci USA 80:2112-2116.
102. Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW. 2006. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 27:736-741.
103. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. 2004. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
104. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH. 1982. Mechanism of activation of a human oncogene. Nature 300:143-149.
105. Takahashi K, Kogaki S, Kurotobi S, Nasuno S, Ohta M, Okabe H, Wada K, Sakai N, Taniike M, Ozono K. 2005. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. Eur J Pediatr 164:497-500.
106. Takai Y, Sasaki T, Matozaki T. 2001. Small GTP-binding proteins. Physiol Rev 81:153-208.
107. Taparowsky E, Suard Y, Fasano O, Shimizu K, Goldfarb M, Wigler M. 1982. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 300:762-765.
108. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. 2001. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468.
109. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD. 2002. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563.
110. Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, Hahlen K, Hasle H, Licht JD, Gelb BD, 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34:148-150.
111. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Arico M, Masera G, Basso G, Sorcini M, Gelb BD, Biondi A. 2004. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104:307-313.
112. Tartaglia M, Gelb BD. 2005. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 48:81-96.
113. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, Zampino G, Burgt I, Palleschi A, Petrucci TC, Sorcini M, Schoch C, Foa R, Emanuel PD, Gelb BD. 2006. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 78:279-290.
114. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. 2007. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 39:75-79.
115. Tuveson DA, Shaw AT, Willis NA, Silver DR. Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375-387.
116. van Den Berg H, Hennekam RC. 1999. Acute lymphoblastic leukaemia in a patient with cardiofaciocutaneous syndrome. J Med Genet 36:799-800.
117. van Steensel MA, Vreeburg M, Peels C, van Ravenswaaij-Arts CM, Bijlsma E, Schrander-Stumpel CT, van Geel M. 2006. Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 15:731-734.
118. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. 2004. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
119. Wieczorek D, Majewski F, Gillessen-Kaesbach G. 1997. Cardio- faciocutaneous (CFC) syndrome - a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Clin Genet 52:37-46.
120. Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bemal R, Rapp UR, Zimmer A. 1997. Endothelial apoptosis in Braf-deficient mice. Nat Genet 16:293-297.
121. Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, Okuyama T, Horikawa R, Tanaka T, Ogata T. 2004a. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with noonan syndrome. J Clin Endocrinol Metab 89:3359-3364.
122. Yoshida R, Miyata M, Nagai T, Yamazaki T, Ogata T. 2004b. A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. Am J Med Genet A 128:63-66.
123. Yoshida R, Nagai T, Hasegawa T, Kinoshita E, Tanaka T, Ogata T. 2004c. Two novel and one recurrent PTPN11 mutations in LEOPARD syndrome. Am J Med Genet A 130:432-434.
124. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, Pogna EA, De Feo E, Delogu A, Sarkozy A, Atzeri F, Selicorni A, Rauen KA, Cytrynbaum CS, Weksberg R, Dallapiccola B, Ballabio A, Gelb BD, Neri G, Tartaglia M. 2006. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 28:265-272.
125. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A. 2004. Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368-374.
126. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, Mundlos S, Quante AS, Raskin S, Schnabel D, Wehner LE, Kratz CP, Horn D, Kutsche K. 2007a. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 44:131-135.
127. Zenker M, Voss E, Reis A. 2007b. Mild variable Noonan syndrome in a family with a novel PTPN11 mutation. Eur J Med Genet 50:43-47.
128. Zheng CF, Guan KL. 1993. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem 268:11435-11439.